Bruker’s second quarter was marked by revenue and earnings results that fell below Wall Street’s expectations, leading to a significant negative market reaction. Management cited persistent weakness across its core life sciences research and industrial markets, particularly due to delayed U.S. academic funding and slow stimulus activity in China. CEO Frank Laukien described the quarter as "challenging," noting that “global tariffs, pharma pricing and economic uncertainty… have delayed biopharma and industrial research instrumentation investments.” Management acknowledged that its mitigation efforts would take several quarters to benefit operating results, with immediate impacts limited.
Is now the time to buy BRKR? Find out in our full research report (it’s free).
Bruker (BRKR) Q2 CY2025 Highlights:
- Revenue: $797.4 million vs analyst estimates of $809.2 million (flat year on year, 1.5% miss)
- Adjusted EPS: $0.32 vs analyst expectations of $0.42 (23.4% miss)
- Adjusted EBITDA: $96.6 million vs analyst estimates of $123.6 million (12.1% margin, 21.9% miss)
- The company dropped its revenue guidance for the full year to $3.47 billion at the midpoint from $3.52 billion, a 1.4% decrease
- Management lowered its full-year Adjusted EPS guidance to $2 at the midpoint, a 18% decrease
- Operating Margin: 1.5%, down from 6% in the same quarter last year
- Organic Revenue fell 7% year on year vs analyst estimates of 2.6% declines (443 basis point miss)
- Market Capitalization: $4.91 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Bruker’s Q2 Earnings Call
- Puneet Souda (Leerink Partners) questioned the lack of backlog support and visibility into fourth-quarter recovery. CEO Frank Laukien explained backlog utilization is constrained by customer delivery schedules, and confirmed confidence in a typical year-end ramp.
- Tycho W. Peterson (Jefferies) pressed on the timing and scope of cost reductions. Laukien clarified that initial savings began earlier in the year, with $30 million impacting this year and full commitment to the $100–$120 million target regardless of market growth.
- Brandon Couillard (Wells Fargo) asked about second-quarter cash flow burn and CapEx. CFO Gerald Herman attributed outflows to unusual tax payments and stated CapEx would decrease in the second half as ongoing projects conclude.
- Luke Sergott (Barclays) inquired about the outlook for China stimulus and academic funding dynamics. Laukien responded that high-end research stimulus in China had not yet materialized, though customer optimism persists, and described expectations for a more geographically distributed U.S. funding environment longer term.
- Patrick Donnelly (Citi) questioned the visibility and confidence around the significant fourth-quarter profit ramp. Herman and Laukien explained that a seasonal fourth-quarter surge and cost savings underpin their expectations for improved profitability.
Catalysts in Upcoming Quarters
In the quarters ahead, our analysts will closely watch (1) the pace and impact of Bruker’s cost reduction efforts on margins, (2) the timing and magnitude of U.S. and China research funding releases, and (3) adoption rates for newly launched proteomics and spatial biology instruments. The evolution of global tariff policies and any uptick in consumables or diagnostics demand will also be important factors in evaluating Bruker’s execution and recovery potential.
Bruker currently trades at $32.49, down from $37.97 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
